Advertisement

Digestive Diseases and Sciences

, Volume 41, Issue 2, pp 315–321 | Cite as

IL-1β and TNF-α produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C

  • Yasuhiro Kishihara
  • Jun Hayashi
  • Eriko Yoshimura
  • Kouzaburo Yamaji
  • Koya Nakashima
  • Seizaburo Kashiwagi
Liver: Infectious, Inflammatory, And Metabolic Disorders

Abstract

We investigated the spontaneous and phytohemagglutinin-stimulated production of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) by peripheral blood mononuclear cells in patients with chronic hepatitis C during treatment with interferon-α (IFN-α). Spontaneous productions of these were significantly higher in patients with chronic hepatitis C than in healthy subjects. For patients prescribed interferon, stimulated production of TNF-α was significantly higher in complete responders than in partial responders, but the differences were small between the other cytokine levels and outcome of IFN treatment. Spontaneous production of these cytokines was higher in patients with genotype III with complete response than in genotype III patients with a partial response, but this was not the case in patients with genotype II. There was a negative correlation between these cytokines and histological activity index. Spontaneous production of cytokines was decreased only in complete responders after the administration of interferon. These data suggest that the elevated production of cytokines in patients with chronic hepatitis C may be due to host response to the virus, and monitoring cytokines along with alanine aminotransferase and hepatitis C virus RNA during treatment may provide more precise information of the effectiveness of therapy.

Key words

chronic hepatitis C interferon therapy IL-1 TNF 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arai K, Lee F, Miyajima A, Miyataka S, Argi N, Yokota T: Cytokines: Coordinators of immune and inflammatory responses. Annu Rev Biochem 59:783–836, 1990PubMedGoogle Scholar
  2. 2.
    Dinarello CA, Mier JW: Current concepts, lymphokines. N Engl J Med 317:940–945, 1987PubMedGoogle Scholar
  3. 3.
    Ozyilkan E, Tatar G, Hacibektasoglu A, Kayhan B, Telatar H: Impaired lipopolysaccharide-induced interleukin-1-beta production in patients with anti-hepatitis C virus antibody-positive chronic liver disease. Scand J Gastroenterol 29:280–283, 1994PubMedGoogle Scholar
  4. 4.
    Muller C, Knoflach P, Zielinski CC: Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of patients with acute and chronic viral hepatitis. Dig Dis Sci 38:477–481, 1993PubMedGoogle Scholar
  5. 5.
    Anastassakos C, Alexander GJM, Wolstencroft RA, Avery JA, Portmann BG, Panayi GS, Dumonde DC, Eddleston ALWF, Williams R: Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology 94:999–1005, 1988PubMedGoogle Scholar
  6. 6.
    Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M: Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 10:769–773, 1989PubMedGoogle Scholar
  7. 7.
    Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C: Serum levels of cytokines in chronic liver diseases. Gastroenterology 103;264–274, 1992PubMedGoogle Scholar
  8. 8.
    Lazzari FD, Fabris P, Floreani A, Bortolami M, Venturi C, Chiaramonte M, Naccarato R: Tumor necrosis factor-alpha behavior in serum during recombinant-alpha-2b-interferon treatment of chronic viral hepatitis. Eur J Gastroenterol Hepatol 6:625–628, 1994Google Scholar
  9. 9.
    Daniels HM, Meager A, Eddelston ALWF, Alexander GJM, Williams R: Spontaneous production of tumor necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancer 335:875–877, 1990Google Scholar
  10. 10.
    Dinarello CA: Interleukin-1 and its biologically related cytokines. Adv Immunol 44:153–205, 1989PubMedGoogle Scholar
  11. 11.
    Oppenheim JJ, Kovaks EJ, Matsushima K, Durum SK: There is more than one interleukin 1. Immunol Today 7:45–56, 1986Google Scholar
  12. 12.
    Scheurich P, Thoma B, Ucer U, Pfizenmaier K: Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 138:1786–1790, 1987PubMedGoogle Scholar
  13. 13.
    Wong GHW, Goeddel DV: Tumor necrosis alpha and beta inhibit virus replication and synergize with interferon. Nature 323:819–822, 1986PubMedGoogle Scholar
  14. 14.
    Mestan J, Digel W, Mittnacht S: Antiviral effects of recombinant tumor necrosis factorin vitro. Nature 323:816–819, 1986PubMedGoogle Scholar
  15. 15.
    Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie AM, Peters M, Waggoner JG, Park Y, Jones EA: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 315:1575–1578, 1986PubMedGoogle Scholar
  16. 16.
    Hayashi J, Nakashima K, Noguichi A, Hirata M, Akazawa K, Kashiwagi S: Antiviral effect of interferon therapy for patients with chronic hepatitis C. Antiviral Chem Chemother 3:305–309, 1992Google Scholar
  17. 17.
    Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Kashiwagi S: A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 89:2151–2156, 1994PubMedGoogle Scholar
  18. 18.
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435, 1981PubMedGoogle Scholar
  19. 19.
    Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Satoh K, Tsuda F, Miyakawa Y, Mayumi M: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 73:673–679, 1992PubMedGoogle Scholar
  20. 20.
    Kaneko S, Murakami S, Unoura M, Kobayashi K: Quantitation of hepatitis C virus RNA by competitive polymerase chain reaction. J Med Virol 37:278–282, 1992PubMedGoogle Scholar
  21. 21.
    Tanaka K, Ishikawa E, Ohmoto Y, Hirai Y:In vitro production of human interleukin 1α and interleukin 1β by peripheral blood mononuclear cells examined by sensitive sandwitch enzyme immunoassay. Eur J Immunol 17:1527–1530, 1989Google Scholar
  22. 22.
    Takehara T, Hayashi N, Mita E, Hagiwara H, Ueda K, Katayama K, Kasahara A, Fusamoto H, Kamada T: Detection of the minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: Implications for hepatitis C virus replication in infected tissue. Hepatology 15:387–390, 1992PubMedGoogle Scholar
  23. 23.
    Deviere J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, Dupont E: Excessivein vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 11:628–634, 1990PubMedGoogle Scholar
  24. 24.
    Di Bisceglie A, Hoofnagle JH: Therapy of chronic hepatitis C with alpha-interferon: The answer? Or more questions? Hepatology 13:601–603, 1991PubMedGoogle Scholar
  25. 25.
    Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J: Prediction of the response of chronic hepatitis C to interferon alpha: A statistical analysis of pretreatment variables. Gut 34:1714–1717, 1993PubMedGoogle Scholar
  26. 26.
    Noguchi A, Hayashi J, Nakashima K, Hirata M, Ikematsu H, Kashiwagi S: HBsAg subtypes among HBsAg carriers in Okinawa, Japan: Evidence of an important relationship in seroconversion from HBeAg to anti HBe. J Infect 28:141–150, 1994PubMedGoogle Scholar
  27. 27.
    Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, Hayashi Y, Jimori T, Suzuki S: Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 18:1319–1325, 1993PubMedGoogle Scholar
  28. 28.
    Tilg H, Mier JW, Vogel W, Aulitzky WE, Wiedermann CJ, Vannier E, Huber C, Dinarello CA: Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 150:4687–4692, 1993PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Yasuhiro Kishihara
    • 1
  • Jun Hayashi
    • 1
  • Eriko Yoshimura
    • 1
  • Kouzaburo Yamaji
    • 1
  • Koya Nakashima
    • 1
  • Seizaburo Kashiwagi
    • 1
  1. 1.The Department of General MedicineKyushu University HospitalFukuokaJapan

Personalised recommendations